MelanomaNCT00237965
The Use of Mole Mapping Diagrams to Increase Skin Self Examination Accuracy
A study testing Mole Mapping Diagram in people with Melanoma, run by Brown University.
Trial summary
This study aims to improve Skin Self-Examination accuracy by a simple cost effective intervention requiring participants to complete a mole-mapping diagram. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Melanoma
- What is being tested?
- Mole Mapping Diagram
- Type of treatment
- Lifestyle or therapy programme
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Start not givento not given
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Male and female subjects above age 18 of any ethnicity will be enrolled in this study.
Who cannot join
- Subjects will be excluded from the study if they have significant skin disease which would not allow manipulation of their photographs consistent with the rest of the subjects.
- Since the study instructions are in English, Non-English speakers will be excluded.
- Those with co-morbidity sufficiently severe to prevent them from being able to perform a SSE will be excluded.
- In addition, those with cognitive impairment who are unable to give informed consent, or to understand the study instructions given to them, will be excluded.
About this study
This study aims to improve Skin Self-Examination accuracy by a simple cost effective intervention requiring participants to complete a mole-mapping diagram.
- Conditions
- Melanoma
- Being tested
- Mole Mapping Diagram
- Keywords
- Skin Self Examination, Mole Mapping Diagram, Melanoma
- Medical subject headings
- Melanoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mole Mapping DiagramBehavioural
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Oct 2005 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MelanomaStudies of the same condition, open and under way.
- More trials run by Brown UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
Sponsor and investigators
- Lead sponsor
- Brown University
- Sponsor type
- University, hospital or other
- Investigators
- Martin A Weinstock, MD, Ph.D, Principal investigator, Veterans Affairs Medical Center Providence, RI
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00237965
- Sponsor's protocol ID
- 00001402
- Status last verified
- May 2004
- First submitted
- 11 Oct 2005
- Last updated
- 13 Oct 2005
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2005. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Use of Mole Mapping Diagrams to Increase Skin Self Examination Accuracy
- ClinicalTrials.gov ID
- NCT00237965
- Acronym / sponsor ID
- 00001402
- Conditions
- Melanoma
- Keywords
- Skin Self Examination, Mole Mapping Diagram, Melanoma
- Study type
- Interventional
- Recruitment status
- Completed
- Lead sponsor
- Brown UniversityUniversity, hospital or other
- First posted
- 13 Oct 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to improve Skin Self-Examination accuracy by a simple cost effective intervention requiring participants to complete a mole-mapping diagram.
Study design
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Male and female subjects above age 18 of any ethnicity will be enrolled in this study.
Key exclusion criteria (4 listed)
- Subjects will be excluded from the study if they have significant skin disease which would not allow manipulation of their photographs consistent with the rest of the subjects.
- Since the study instructions are in English, Non-English speakers will be excluded.
- Those with co-morbidity sufficiently severe to prevent them from being able to perform a SSE will be excluded.
- In addition, those with cognitive impairment who are unable to give informed consent, or to understand the study instructions given to them, will be excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mole Mapping Diagram | Behavioural | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2005.
Related trials for Melanoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 1
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
Melanoma
Active, not recruitingPhase 1/2
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
Melanoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Martin A Weinstock, MD, Ph.D principal investigator
Veterans Affairs Medical Center Providence, RI
Questions about this trial
What is this clinical trial studying?
A study testing Mole Mapping Diagram in people with Melanoma, run by Brown University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Oct 2005. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2005.